为了深入贯彻落实习近平总书记关于做好科普工作重要论述，全国政协发挥人才荟萃、智力密集的优 势，开设了"委员科学讲堂"。讲堂邀请政协委员中的名家，面向社会举办科普讲座，自2023年9月创立 以来，迄今已举办16场。通过"委员科学讲堂"，不同领域的著名科学家展现了政协委员为国履职、为民 尽责的担当，普及科学知识、倡导科学方法、传播科学思想、弘扬科学精神，为形成热爱科学、崇尚科 学的社会风尚贡献政协力量。 来源：中国青年报客户端 能不能赶超国外，为中国学界争光，是曹雪涛做科研很重要的动力。尽管也收到过国外实验室的邀请， 他选择了坚守在国内，见证了中国科技事业从原来的跟踪模仿，到某些领域并跑，甚至在某些尖端领域 和关键领域能够有自己一席之地。"有兴趣，再加上有责任感，才能把事做好。"曹雪涛总结。 在讲座中，曹雪涛以"免疫与疾病防治"为题，阐述免疫学在疾病预防、诊断和治疗中的关键作用，展现 免疫学领域的前沿成果与战略发展方向。"做基础研究还是要有目标和问题导向，临床疾病的诊治需求 永远是我们免疫学研究的动力。"曹雪涛表示，希望以临床疾病诊治需求为牵引，推进免疫学转化应用 和学科发展；以前沿技术研发及应用为突破口，推动免 ...

转自：中国科学报 2025年，免疫学研究在基础、转化乃至临床等方面均取得了显著进展，尤其在生物机械力免疫、免疫代 谢、神经免疫以及免疫衰老等方向有重大突破。本文总结了2025年免疫学领域的最新研究成果。 一、生物力免疫 纪念斯隆·凯特琳癌症中心Richard M. White教授实验室发现黑色素瘤细胞在受到微环境机械挤压时，会 迅速形成"护核笼"，进而通过重塑染色质，激活相关转录程序，推动细胞从增殖状态切换到侵袭态。该 研究明确了外力作为调控肿瘤细胞命运和耐药的重要环境信号，为理解肿瘤进展及开发干预癌细胞可塑 性提供了新视角。 二、免疫代谢 2025年，生物机械力与免疫研究持续升温。越来越多的研究表明，免疫细胞不仅能感知化学信号，还能 将拉伸、压缩、剪切等机械刺激转化为精细的免疫调控信息。 我们团队首次利用生物力学信号成功解偶联CAR-T细胞的增殖与分化程序，建立了高效制备干性CAR-T 细胞的完整技术，仅4.5天即可制备出应用级的干性CAR-T细胞，针对多种实体肿瘤表现出更强的肿瘤 浸润和持久抗肿瘤效应。这项研究为突破实体瘤CAR-T治疗瓶颈提供了全新理论框架和可转化路径。 美国西奈山伊坎医学院胡宏镇教授团 ...

智通财经APP获悉，礼来(LLY.US)确认已同意以每股14美元的现金收购Ventyx Biosciences (VTYX.US)。 根据周三发布的一份声明，该交易的总股权价值约为 12 亿美元。该交易不附加任何融资条件，预计将 于今年上半年完成。美银证券担任礼来的独家财务顾问，杰富瑞担任Ventyx的首席财务顾问。 总部位于圣地亚哥的Ventyx专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物，礼来收购 该公司旨在拓展其在免疫学领域的业务。 与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 ...

与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 据报道，礼来(LLY.US)正就以超过10亿美元的价格收购Ventyx Biosciences(VTYX.US)进行深入谈判，以 拓展其在免疫学领域的业务。截至发稿，Ventyx股价在美股夜盘交易中上涨62.59%，至16.34美元。这 家总部位于圣地亚哥的生物技术公司专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物， 按此价格计算，其市值将增加4.339亿美元。Ventyx收购案的报道正值制药行业准备参加在旧金山举行 的摩根大通医疗保健大会之际，该大会历来是并购交易 ...

Core Insights - The 2025 Nobel Prize in Physiology or Medicine was awarded for the discovery of regulatory T cells, which play a crucial role in immunology and have potential applications in treating diseases like cancer and autoimmune disorders [1][5][13] - Despite the excitement surrounding this discovery, there are currently no approved drugs on the market that are based on regulatory T cells [3][4] - The timeline for potential therapies utilizing regulatory T cells is uncertain, with estimates suggesting it could take up to 20 years for effective treatments to emerge [5][16] Industry Trends - Several biotechnology companies founded by the Nobel laureates are focused on developing therapies that target regulatory T cells, but their products are still in early research stages [6] - The overall outlook for cell therapies, aside from CAR-T, is not optimistic, with some companies, like Takeda, halting their investments in cell therapy [7][8] - The advancements in cancer and autoimmune disease treatments over the past 30 years have largely not involved regulatory T cells, with significant breakthroughs coming from other areas of immunology [10][11] Research and Development Challenges - The journey from scientific discovery to practical application is lengthy, and the complexity of diseases may limit the effectiveness of therapies targeting regulatory T cells [16][18] - Potential safety concerns and manufacturing challenges could hinder the development of drugs based on regulatory T cells, as altering their function may lead to severe adverse reactions [18]

Core Viewpoint - Japan has produced three Nobel Prize winners in the field of immunology, highlighting its strong research capabilities despite recent declines in global rankings [12]. Group 1: Key Contributions of Japanese Researchers - Shimon Sakaguchi, the latest Nobel laureate, discovered that removing specific immune cells can activate immune responses, leading to autoimmune diseases [3][5]. - The research on regulatory T cells by Sakaguchi has significant implications for cancer treatment, with Rakuten Medical initiating clinical trials for a new cancer therapy targeting these cells [5]. - The emergence of gene manipulation technologies in the 1970s spurred global interest in immunology, with Japanese researchers making notable contributions [7]. Group 2: Historical Context and Influential Figures - Notable figures in Japanese immunology include Shohei Hayashi, who made groundbreaking discoveries in oxygenase and was considered a strong candidate for the Nobel Prize [9]. - Tadao Takahashi and Tadamitsu Kishimoto are other key scholars who have significantly advanced the field, with Kishimoto's work leading to the development of blockbuster drugs like Actemra [10][11]. - The legacy of these researchers has fostered a robust environment for immunology in Japan, with many students and successors continuing their impactful work [9][10]. Group 3: Current Challenges and Future Directions - Despite its historical strengths, Japan's scientific competitiveness is declining, necessitating policies to nurture talent and translate research into innovation [12][13].

Core Viewpoint - The article announces the launch of the open-access journal "Immunity & Inflammation," focusing on significant scientific issues and advancements in the fields of immunology and inflammation [2][4]. Group 1: Journal Overview - "Immunity & Inflammation" is co-edited by prominent figures in immunology, including Nobel laureates and leading researchers from various countries [2][5]. - The journal aims to bridge foundational insights with medical innovations, publishing high-quality original research, reviews, and highlights across basic, translational, and clinical research [6]. Group 2: Research Focus - The journal particularly welcomes studies exploring the dual nature of inflammation, inflammation-driven diseases, novel anti-inflammatory interventions, and groundbreaking findings in immune regulation [6]. - It encourages interdisciplinary research, including the use of artificial intelligence and digital health technologies, and aims to establish new standards in relevant research and practice areas [6]. Group 3: Editorial Commitment - The journal is committed to maintaining the highest standards of scientific ethics, integrity, transparency, and reproducibility [6][7]. - It invites global scientific communities to collaborate and contribute to making "Immunity & Inflammation" a vibrant and impactful academic platform [7].

Group 1 - The article introduces Professor Song Zhenju, who holds multiple prestigious positions in emergency medicine and clinical research, including Director of the Emergency Department at Fudan University Zhongshan Hospital and Vice President of the same hospital [1] - Professor Song has led numerous national and provincial research projects, published extensively in high-impact journals, and holds multiple patents, indicating a strong research background and contributions to the field [1] Group 2 - The research directions focus on Acute Respiratory Distress Syndrome (ARDS) mechanisms and interventions, organ damage from sepsis, and mechanisms and interventions for acute poisoning [6] Group 3 - Recruitment is open for postdoctoral positions in fields such as Clinical Medicine, Life Sciences, Biology, Biomedical Engineering, and Pharmacy [3] - Candidates must be under 35 years old, have a strong academic background, and have published at least one SCI paper [5] Group 4 - Compensation will follow national and Fudan University standards, with additional rewards for outstanding performance during the contract period [7] Group 5 - Applicants are required to submit a detailed CV, proof of doctoral degree, and 1-3 representative papers [8] - Contact information for applications is provided, with specific instructions for email subject lines [9][10]

Group 1 - Sanofi is acquiring Blueprint Medicines Corp for $9.1 billion in equity value, enhancing its pipeline in rare immune diseases [1][2] - The acquisition price is set at $129 per share, representing a 27% premium over Blueprint's closing price last Friday [1] - Blueprint shareholders will receive a contingent value right (CVR) worth an additional $2 to $4 per share if the BLU-808 drug meets certain development and regulatory milestones [1] Group 2 - This acquisition reflects Sanofi's ambition to establish a leadership position in immunology, following a previous announcement to acquire Dren Bio, Inc. for up to $1.9 billion [1] - Blueprint Medicines has a strong clinical network among specialists and a pipeline that includes several immunotherapy candidates [2] - The total value of the transaction, including potential CVR payments, is approximately $9.5 billion, with Sanofi expecting the deal to close in the third quarter without significant impact on its 2025 financial guidance [2]